BMO Capital Reiterates Market Perform Rating on Biogen (BIIB), "Encouraged with Potential New Leadership... Remain on Sidelines Given Risk Into Lecanemab Data"
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $238.00 price target on Biogen (NASDAQ: BIIB), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
